Statera Biopharma, Inc. (STAB)

$0.245

-0.02 (-7.58%)
Rating:
Recommendation:
-
Symbol STAB
Price $0.245
Beta 0.000
Volume Avg. 1.00M
Market Cap 12.255M
Shares () -
52 Week Range 0.2-4.66
1y Target Est -
DCF Unlevered STAB DCF ->
DCF Levered STAB LDCF ->
ROE -99.26% Strong Sell
ROA -18.78% Sell
Operating Margin -
Debt / Equity 18.40% Neutral
P/E -
P/B 0.09 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest STAB news


Healthcare
Biotechnology
NASDAQ Capital Market

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.